Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PDSB PDS Biotechnology Corp
- Stocks
- Healthcare
- NASDAQ: PDSB
Price (delayed)
$1.22
Market cap
$55.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$35.52M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
Highlights
PDS Biotechnology's EPS has increased by 26% YoY and by 12% QoQ
PDS Biotechnology's net income has increased by 12% YoY and by 7% from the previous quarter
The quick ratio is down by 41% YoY and by 10% from the previous quarter
The equity has contracted by 27% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of PDSB
Market
Valuations
Earnings
Shares outstanding
45.4M
Market cap
$55.38M
Enterprise value
$35.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$36.32M
Net income
-$37.61M
EBIT
-$36.32M
EBITDA
-$36.3M
Free cash flow
-$35.06M
Per share
Balance sheet
Liquidity
EPS
-$1.03
EPS diluted
-$1.03
Free cash flow per share
-$0.96
Book value per share
$0.51
Revenue per share
$0
TBVPS
$1.24
Total assets
$45.36M
Total liabilities
$26.35M
Debt
$21.83M
Equity
$19M
Working capital
$27.97M
Debt to equity
1.15
Current ratio
2.64
Quick ratio
2.44
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-66.2%
Return on equity
-137.9%
Return on invested capital
-360.3%
Return on capital employed
-128.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PDSB stock price
How has the PDS Biotechnology stock price performed over time
Intraday
5.17%
1 week
-8.27%
1 month
30.47%
1 year
-69.65%
YTD
-25.15%
QTD
2.52%
Financial performance
How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.32M
Net income
-$37.61M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 16% YoY and by 8% from the previous quarter
PDS Biotechnology's net income has increased by 12% YoY and by 7% from the previous quarter
Price vs fundamentals
How does PDSB's price correlate with its fundamentals
Growth
What is PDS Biotechnology's growth rate over time
Valuation
What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
2.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 26% YoY and by 12% QoQ
The P/B is 43% lower than the last 4 quarters average of 4.2 and 40% lower than the 5-year quarterly average of 4.0
The equity has contracted by 27% YoY and by 14% from the previous quarter
Efficiency
How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has plunged by 50% YoY and by 2.9% from the previous quarter
The ROA is up by 4.1% YoY
Dividends
What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PDSB.
Financial health
How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 72% more than its total liabilities
The quick ratio is down by 41% YoY and by 10% from the previous quarter
PDSB's current ratio is down by 39% year-on-year and by 7% since the previous quarter
PDS Biotechnology's debt is 15% higher than its equity
The equity has contracted by 27% YoY and by 14% from the previous quarter
The debt to equity is up by 26% year-on-year and by 2.7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.